Advances in basic and clinical research of flumatinib
10.3760/cma.j.cn121090-20231211-00304
- VernacularTitle:氟马替尼基础与临床研究进展
- Author:
Lei JIANG
1
;
Mingzhen YANG
Author Information
1. 安徽医科大学第一附属医院血液内科，安徽省公共卫生临床中心，合肥 230032
- From:
Chinese Journal of Hematology
2024;45(6):621-624
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myelogenous leukemia (CML) is a hematological malignancy originating from the pluripotent hematopoietic stem cells. Imatinib is the first generation of small molecule tyrosine kinase inhibitors (TKI) that revolutionized the treatment of CML. Flumatinib, as a novel oral TKI that independently developed in China, which can be used as a preferred treatment for CML. Basic researches suggested that the inhibitory effect of flumatinib on CML cell lines is stronger than imatinib. Flumatinib demonstrated that it has better efficacy than imatinib on CML in clinical trials and in real world studies. Flumatinib also showed a higher potency against CML with specific mutations, Ph + acute lymphoblastic leukemia and some solid tumors. The adverse events are manageable and tolerable.
